{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:34:24Z","timestamp":1793284464581,"version":"4.5.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12185-026-04283-2","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:20:18Z","timestamp":1790572818000},"page":"601-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current management of central nervous system involvement in chronic lymphocytic leukemia\/small lymphocytic lymphoma"],"prefix":"10.1007","volume":"124","author":[{"given":"Yuanli","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Khawandanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimu","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"4283_CR1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","volume":"329","author":"M Shadman","year":"2023","unstructured":"Shadman M. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA. 2023;329:918\u201332. https:\/\/doi.org\/10.1001\/jama.2023.1946.","journal-title":"JAMA"},{"key":"4283_CR2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3324\/haematol.2015.136556","volume":"101","author":"P Strati","year":"2016","unstructured":"Strati P, Uhm JH, Kaufmann TJ, Nabhan C, Parikh SA, Hanson CA, et al. Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. Haematologica. 2016;101:458\u201365. https:\/\/doi.org\/10.3324\/haematol.2015.136556.","journal-title":"Haematologica"},{"key":"4283_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1212\/wnl.46.1.19","volume":"46","author":"SC Cramer","year":"1996","unstructured":"Cramer SC, Glaspy JA, Efird JT, Louis DN. Chronic lymphocytic leukemia and the central nervous system. Neurology. 1996;46:19\u201325. https:\/\/doi.org\/10.1212\/wnl.46.1.19.","journal-title":"Neurology"},{"key":"4283_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s0140-6736(74)92511-2","volume":"1","author":"E Reske-Nielsen","year":"1974","unstructured":"Reske-Nielsen E, Petersen JH, Sogaard H, Jensen KB. Letter: Leukaemia of the central nervous system. Lancet Lond Engl. 1974;1:211\u20132. https:\/\/doi.org\/10.1016\/s0140-6736(74)92511-2.","journal-title":"Lancet Lond Engl"},{"key":"4283_CR5","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.clineuro.2007.07.021","volume":"109","author":"CPE Lange","year":"2007","unstructured":"Lange CPE, Brouwer RE, Brooimans R, Vecht CJ. Leptomeningeal disease in chronic lymphocytic leukemia. Clin Neurol Neurosurg. 2007;109:896\u2013901. https:\/\/doi.org\/10.1016\/j.clineuro.2007.07.021.","journal-title":"Clin Neurol Neurosurg"},{"key":"4283_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/bjh.14387","volume":"176","author":"A Wanquet","year":"2017","unstructured":"Wanquet A, Birsen R, Bonnet C, Boubaya M, Choquet S, Dupuis J, et al. Management of central nervous system involvement in chronic lymphocytic leukaemia: a retrospective cohort of 30 patients. Br J Haematol. 2017;176:37\u201349. https:\/\/doi.org\/10.1111\/bjh.14387.","journal-title":"Br J Haematol"},{"key":"4283_CR7","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00277-018-3329-2","volume":"97","author":"NKLM Timmers","year":"2018","unstructured":"Timmers NKLM, de Maar JS, van Kruijsdijk RCM, Klein SK. Central nervous system localisation of chronic lymphocytic leukaemia, description of two very distinct cases and a review of the literature. Ann Hematol. 2018;97:1627\u201332. https:\/\/doi.org\/10.1007\/s00277-018-3329-2.","journal-title":"Ann Hematol"},{"key":"4283_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/neup.12525","volume":"39","author":"R Otani","year":"2019","unstructured":"Otani R, Uzuka T, Matsuda H, Higuchi F, Kim P, Ueki K. Brain invasion by chronic lymphocytic leukemia. Neuropathology. 2019;39:54\u20137. https:\/\/doi.org\/10.1111\/neup.12525.","journal-title":"Neuropathology"},{"key":"4283_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s11060-011-0636-z","volume":"106","author":"AA Moazzam","year":"2012","unstructured":"Moazzam AA, Drappatz J, Kim RY, Kesari S. Chronic lymphocytic leukemia with central nervous system involvement: report of two cases with a comprehensive literature review. J Neurooncol. 2012;106:185\u2013200. https:\/\/doi.org\/10.1007\/s11060-011-0636-z.","journal-title":"J Neurooncol"},{"key":"4283_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jns.2008.11.003","volume":"277","author":"C Denier","year":"2009","unstructured":"Denier C, Tertian G, Ribrag V, Lozeron P, Bilhou-Nabera C, Lazure T, et al. Multifocal deficits due to leukemic meningoradiculitis in chronic lymphocytic leukemia. J Neurol Sci. 2009;277:130\u20132. https:\/\/doi.org\/10.1016\/j.jns.2008.11.003.","journal-title":"J Neurol Sci"},{"key":"4283_CR11","doi-asserted-by":"publisher","first-page":"e187","DOI":"10.1097\/WNO.0000000000001263","volume":"42","author":"JL Parker","year":"2022","unstructured":"Parker JL, Mays KM, Pratibhu PP, Pick PW, Block DK. Optic perineuritis presenting as the initial manifestation of central nervous system involvement in Rai stage 0 chronic lymphocytic leukemia. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2022;42:e187\u201391. https:\/\/doi.org\/10.1097\/WNO.0000000000001263.","journal-title":"J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc"},{"key":"4283_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.clml.2011.10.005","volume":"12","author":"R Lopes da Silva","year":"2012","unstructured":"Lopes da Silva R. Spectrum of neurologic complications in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2012;12:164\u201379. https:\/\/doi.org\/10.1016\/j.clml.2011.10.005.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4283_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000204593","volume":"88","author":"P Ruiz","year":"2009","unstructured":"Ruiz P, Moezzi M, Chamizo W, Ganjei P, Whitcomb CC, Rey LC. Central nervous system expression of a monoclonal paraprotein in a chronic lymphocytic leukemia patient. Acta Haematol. 2009;88:37\u201340. https:\/\/doi.org\/10.1159\/000204593.","journal-title":"Acta Haematol"},{"key":"4283_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.clml.2012.12.007","volume":"13","author":"O Benjamini","year":"2013","unstructured":"Benjamini O, Jain P, Schlette E, Sciffman JS, Estrov Z, Keating M. Chronic lymphocytic leukemia with central nervous system involvement: a high-risk disease? Clin Lymphoma Myeloma Leuk. 2013;13:338\u201341. https:\/\/doi.org\/10.1016\/j.clml.2012.12.007.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4283_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1186\/1756-0500-7-645","volume":"7","author":"SL de Souza","year":"2014","unstructured":"de Souza SL, Santiago F, Ribeiro-Carvalho MdeM, Arn\u00f3bio A, Soares AR, Ornellas MH. Leptomeningeal involvement in B-cell chronic lymphocytic leukemia: a case report and review of the literature. BMC Res Notes. 2014;7:645. https:\/\/doi.org\/10.1186\/1756-0500-7-645.","journal-title":"BMC Res Notes"},{"key":"4283_CR16","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.2214\/AJR.16.16221","volume":"207","author":"JP Guenette","year":"2016","unstructured":"Guenette JP, Tirumani SH, Keraliya AR, Shinagare AB, Ramaiya NH, Jagannathan JP. MRI findings in patients with leukemia and positive CSF cytology: a single-institution 5-year experience. AJR Am J Roentgenol. 2016;207:1278\u201382. https:\/\/doi.org\/10.2214\/AJR.16.16221.","journal-title":"AJR Am J Roentgenol"},{"key":"4283_CR17","first-page":"318","volume":"28","author":"M Ghofrani","year":"2007","unstructured":"Ghofrani M, Tantiwongkosi B, Smith AS, Wasdahl DA. Richter transformation of chronic lymphocytic leukemia presenting as a dural-based non-hodgkin lymphoma mass. AJNR Am J Neuroradiol. 2007;28:318\u201320.","journal-title":"AJNR Am J Neuroradiol"},{"key":"4283_CR18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","volume":"101","author":"JL Rubenstein","year":"2003","unstructured":"Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101:466\u20138. https:\/\/doi.org\/10.1182\/blood-2002-06-1636.","journal-title":"Blood"},{"key":"4283_CR19","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","volume":"25","author":"GD Shah","year":"2007","unstructured":"Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25:4730\u20135. https:\/\/doi.org\/10.1200\/JCO.2007.12.5062.","journal-title":"J Clin Oncol"},{"key":"4283_CR20","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJM Ferreri","year":"2016","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study group-32 (IELSG32) phase 2 trial. Lancet Haematol Elsevier. 2016;3:e217\u201327. https:\/\/doi.org\/10.1016\/S2352-3026(16)00036-3.","journal-title":"Lancet Haematol Elsevier"},{"key":"4283_CR21","doi-asserted-by":"publisher","first-page":"6864","DOI":"10.3390\/ijms21186864","volume":"21","author":"T Breakell","year":"2020","unstructured":"Breakell T, Tacke S, Schropp V, Zetterberg H, Blennow K, Urich E, et al. Obinutuzumab-induced B cell depletion reduces spinal cord pathology in a CD20 double transgenic mouse model of multiple sclerosis. Int J Mol Sci. 2020;21:6864. https:\/\/doi.org\/10.3390\/ijms21186864.","journal-title":"Int J Mol Sci"},{"key":"4283_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1186\/s12885-018-4632-y","volume":"18","author":"T Kim","year":"2018","unstructured":"Kim T, Choi HY, Lee H-S, Jung S-H, Ahn J-S, Kim H-J, et al. Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL). BMC Cancer. 2018;18:729. https:\/\/doi.org\/10.1186\/s12885-018-4632-y.","journal-title":"BMC Cancer"},{"key":"4283_CR23","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.7150\/jca.81795","volume":"14","author":"M Badawi","year":"2023","unstructured":"Badawi M, Menon R, Place AE, Palenski T, Sunkersett G, Arrendale R, et al. Venetoclax penetrates the blood brain barrier: a pharmacokinetic analysis in pediatric leukemia patients. J Cancer. 2023;14:1151\u20136. https:\/\/doi.org\/10.7150\/jca.81795.","journal-title":"J Cancer"},{"key":"4283_CR24","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.3324\/haematol.2018.213157","volume":"104","author":"G Reda","year":"2019","unstructured":"Reda G, Cassin R, Dovrtelova G, Matteo C, Giannotta J, D\u2019Incalci M, et al. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. Haematologica. 2019;104:e222\u20133. https:\/\/doi.org\/10.3324\/haematol.2018.213157.","journal-title":"Haematologica"},{"key":"4283_CR25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00280-018-3546-3","volume":"81","author":"L Goldwirt","year":"2018","unstructured":"Goldwirt L, Beccaria K, Ple A, Sauvageon H, Mourah S. Ibrutinib brain distribution: a preclinical study. Cancer Chemother Pharmacol. 2018;81:783\u20139. https:\/\/doi.org\/10.1007\/s00280-018-3546-3.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4283_CR26","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1182\/blood-2024-204521","volume":"144","author":"IA Nizamuddin","year":"2024","unstructured":"Nizamuddin IA, Epperla N, Malacek M-K, Kahl BS, Wan F, Fischer A, et al. Phase I results of acalabrutinib in combination with durvalumab in primary central nervous system lymphoma: safety, efficacy, and central nervous system penetration. Blood. 2024;144:985. https:\/\/doi.org\/10.1182\/blood-2024-204521.","journal-title":"Blood"},{"key":"4283_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/jha2.830","volume":"5","author":"A Barrett","year":"2023","unstructured":"Barrett A, Eyre TA, Bhuva S, Aljurf M, Fakih RE, Ashshi MA, et al. Complete response of mantle cell lymphoma with central nervous system involvement at diagnosis with acalabrutinib \u2013 case report. EJHaem. 2023;5:238\u201341. https:\/\/doi.org\/10.1002\/jha2.830.","journal-title":"EJHaem"},{"key":"4283_CR28","doi-asserted-by":"publisher","first-page":"760405","DOI":"10.3389\/fonc.2021.760405","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li Y, Zhuang Z, Wang W, Wei C, Zhao D, et al. Preliminary evaluation of zanubrutinib-containing regimens in DLBCL and the cerebrospinal fluid distribution of zanubrutinib: a 13-case series. Front Oncol. 2021;11:760405. https:\/\/doi.org\/10.3389\/fonc.2021.760405.","journal-title":"Front Oncol"},{"key":"4283_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27759","author":"AM Frustaci","year":"2025","unstructured":"Frustaci AM, Zappaterra A, Turri G, Rossi V, Deodato M, Gambacorti-Passerini C, et al. Pirtobrutinib is an effective salvage treatment after ibrutinib in Bing\u2013Neel syndrome. Am J Hematol. 2025. https:\/\/doi.org\/10.1002\/ajh.27759.","journal-title":"Am J Hematol"},{"key":"4283_CR30","unstructured":"DailyMed - FLUDARABINE PHOSPHATE injection, solution [Internet]. [cited 2025 Aug 11]. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=20e5acf0-90b7-45c8-be78-91eaf77c9ac0#s12. Accessed 11 Aug 2025"},{"key":"4283_CR31","first-page":"1985","volume":"3","author":"SM Yule","year":"1997","unstructured":"Yule SM, Price L, Pearson AD, Boddy AV. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin Cancer Res Off J Am Assoc Cancer Res. 1997;3:1985\u201392.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"4283_CR32","unstructured":"DailyMed - CYCLOPHOSPHAMIDE injection, solution [Internet]. [cited 2025 Aug 11]. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=9895cdbd-79cc-4bce-8e16-1c2e045e2592. Accessed 11 Aug 2025"},{"key":"4283_CR33","doi-asserted-by":"publisher","first-page":"694853","DOI":"10.3389\/fimmu.2021.694853","volume":"12","author":"R Zain","year":"2021","unstructured":"Zain R, Vihinen M. Structure-function relationships of covalent and non-covalent BTK inhibitors. Front Immunol. 2021;12:694853. https:\/\/doi.org\/10.3389\/fimmu.2021.694853.","journal-title":"Front Immunol"},{"key":"4283_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40478-024-01763-6","volume":"12","author":"S Lim","year":"2024","unstructured":"Lim S, Kwak M, Kang J, Cesaire M, Tang K, Robey RW, et al. Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model. Acta Neuropathol Commun. 2024;12:56. https:\/\/doi.org\/10.1186\/s40478-024-01763-6.","journal-title":"Acta Neuropathol Commun"},{"key":"4283_CR35","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa2504341","volume":"393","author":"T Munir","year":"2025","unstructured":"Munir T, Girvan S, Cairns DA, Bloor A, Allsup D, Varghese AM, et al. Measurable residual disease\u2013guided therapy for chronic lymphocytic leukemia. N Engl J Med. 2025;393:1177\u201390. https:\/\/doi.org\/10.1056\/NEJMoa2504341.","journal-title":"N Engl J Med"},{"key":"4283_CR36","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Version 2.2026 [Internet]. NCCN. 2025 [cited 2026 Jan 15]. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf. Accessed 15 Jan 2026"},{"key":"4283_CR37","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1200\/JCO.2025.43.16_suppl.7011","volume":"43","author":"CSL Tam","year":"2025","unstructured":"Tam CSL, Ghia P, Shadman M, Munir T, Opat S, Walker P, et al. SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL). J Clin Oncol. 2025;43:7011. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.7011.","journal-title":"J Clin Oncol"},{"key":"4283_CR38","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","volume":"388","author":"B Eichhorst","year":"2023","unstructured":"Eichhorst B, Niemann CU, Kater AP, F\u00fcrstenau M, Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1739\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2213093.","journal-title":"N Engl J Med"},{"key":"4283_CR39","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.3324\/haematol.2014.119123","volume":"100","author":"A Wiestner","year":"2015","unstructured":"Wiestner A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica. 2015;100:1495\u2013507. https:\/\/doi.org\/10.3324\/haematol.2014.119123.","journal-title":"Haematologica"},{"key":"4283_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2211582.","journal-title":"N Engl J Med"},{"key":"4283_CR41","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00277-023-05486-x","volume":"103","author":"S Yin","year":"2024","unstructured":"Yin S, Zheng X, Zhang W, Zhao H, Zhang R, Li W, et al. Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia\/small lymphocytic lymphoma: a systematic review and meta-analysis. Ann Hematol. 2024;103:2231\u201344. https:\/\/doi.org\/10.1007\/s00277-023-05486-x.","journal-title":"Ann Hematol"},{"key":"4283_CR42","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.1182\/blood-2024-211603","volume":"144","author":"Z Tang","year":"2024","unstructured":"Tang Z, Aldapt MB, Chiang C-H, Gong Z. The cardiovascular outcomes difference between acalabrutinib and zanubrutinib: a retrospective cohort study using real-world data. Blood. 2024;144:6783. https:\/\/doi.org\/10.1182\/blood-2024-211603.","journal-title":"Blood"},{"key":"4283_CR43","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017755","author":"T Chatzikonstantinou","year":"2025","unstructured":"Chatzikonstantinou T, Mikhaleva M, Brieghel C, Papangelou C, Minga E, Arrais-Rodrigues C, et al. Central nervous system involvement in CLL: An international retrospective study by ERIC, the european research initiative on CLL. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2025017755.","journal-title":"Blood Adv"},{"key":"4283_CR44","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt TD, Wang XV, Kay NE, Hanson CA, O\u2019Brien S, Barrientos J, et al. Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381:432\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1817073.","journal-title":"N Engl J Med"},{"key":"4283_CR45","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","volume":"24","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:535\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(23)00144-4.","journal-title":"Lancet Oncol"},{"key":"4283_CR46","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1056\/NEJMoa2409804","volume":"392","author":"JR Brown","year":"2025","unstructured":"Brown JR, Seymour JF, Jurczak W, Aw A, Wach M, Illes A, et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025;392:748\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2409804.","journal-title":"N Engl J Med"},{"key":"4283_CR47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2515458","author":"O Al-Sawaf","year":"2025","unstructured":"Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, et al. Fixed-duration versus continuous treatment for chronic lymphocytic leukemia. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2515458.","journal-title":"N Engl J Med"},{"key":"4283_CR48","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000523858","volume":"15","author":"N Karbhari","year":"2022","unstructured":"Karbhari N, Lara-Martinez H, Hill JM Jr, Venetoclax. A novel therapeutic agent for CLL with CNS involvement. Case Rep Oncol. 2022;15:345\u201350. https:\/\/doi.org\/10.1159\/000523858.","journal-title":"Case Rep Oncol"},{"key":"4283_CR49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11060-018-2849-x","volume":"139","author":"A Dara","year":"2018","unstructured":"Dara A, Mook BB, Doorduijn JK, van den Bent MJ, Dinmohamed AG, Bromberg JEC. Efficacy of intrathecal chemotherapy in patients with central nervous system involvement of hematological malignancies: a retrospective analysis. J Neurooncol. 2018;139:117\u201323. https:\/\/doi.org\/10.1007\/s11060-018-2849-x.","journal-title":"J Neurooncol"},{"key":"4283_CR50","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/j.1365-2141.2010.08238.x","volume":"150","author":"J-M Calvo-Villas","year":"2010","unstructured":"Calvo-Villas J-M, Fern\u00e1ndez JA, De La Fuente I, Godoy AC, Mateos MC, Poder\u00f3s C. Intrathecal liposomal cytarabine for treatment of leptomeningeal involvement in transformed (Richter\u2019s syndrome) and non-transformed B-cell chronic lymphocytic leukaemia in Spain: a report of seven cases. Br J Haematol. 2010;150:618\u201320. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08238.x.","journal-title":"Br J Haematol"},{"key":"4283_CR51","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1634\/theoncologist.2018-0619","volume":"24","author":"AV Naydenov","year":"2019","unstructured":"Naydenov AV, Taylor LP. Leptomeningeal carcinomatosis in chronic lymphocytic leukemia: a case report and review of the literature. Oncologist. 2019;24:1237\u201345. https:\/\/doi.org\/10.1634\/theoncologist.2018-0619.","journal-title":"Oncologist"},{"key":"4283_CR52","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0022-3565(25)30311-3","volume":"195","author":"RG Blasberg","year":"1975","unstructured":"Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther. 1975;195:73\u201383.","journal-title":"J Pharmacol Exp Ther"},{"key":"4283_CR53","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(08)70070-6","volume":"9","author":"C-H Pui","year":"2008","unstructured":"Pui C-H, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008;9:257\u201368. https:\/\/doi.org\/10.1016\/S1470-2045(08)70070-6.","journal-title":"Lancet Oncol"},{"key":"4283_CR54","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jacc.2025.10.018","volume":"87","author":"S Ganatra","year":"2026","unstructured":"Ganatra S, Barac A, Armenian S, Cambareri C, Denlinger CS, Dent SF, et al. Diagnosis and management of cardiovascular adverse effects of targeted oncology therapies: Bruton\u2019s tyrosine kinase, immune checkpoint, and vascular endothelial growth factor inhibitors: 2025 ACC concise clinical guidance: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2026;87:654\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2025.10.018.","journal-title":"J Am Coll Cardiol"},{"key":"4283_CR55","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ajh.26788","volume":"98","author":"JJ Castillo","year":"2023","unstructured":"Castillo JJ, Buske C, Trotman J, Sarosiek S, Treon SP. Bruton tyrosine kinase inhibitors in the management of Waldenstr\u00f6m macroglobulinemia. Am J Hematol. 2023;98:338\u201347. https:\/\/doi.org\/10.1002\/ajh.26788.","journal-title":"Am J Hematol"},{"key":"4283_CR56","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.ijrobp.2014.08.004","volume":"90","author":"GV Walker","year":"2014","unstructured":"Walker GV, Shihadeh F, Kantarjian H, Allen P, Rondon G, Kebriaei P, et al. Comprehensive craniospinal radiation for controlling central nervous system leukemia. Int J Radiat Oncol Biol Phys. 2014;90:1119\u201325. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.08.004.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4283_CR57","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","volume":"316","author":"PD Brown","year":"2016","unstructured":"Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316:401\u20139. https:\/\/doi.org\/10.1001\/jama.2016.9839.","journal-title":"JAMA"},{"key":"4283_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010095","volume":"17","author":"N Rippel","year":"2024","unstructured":"Rippel N, Sheppard R, Kittai AS. Updates in the management of Richter transformation. Cancers. 2024;17:95. https:\/\/doi.org\/10.3390\/cancers17010095.","journal-title":"Cancers"},{"key":"4283_CR59","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41375-024-02492-4","volume":"39","author":"PJ Hampel","year":"2025","unstructured":"Hampel PJ, Rabe KG, Wang Y, Hwang SR, Kenderian SS, Muchtar E, et al. Incidence of Richter transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma in the targeted therapy era. Leukemia. 2025;39:503\u20137. https:\/\/doi.org\/10.1038\/s41375-024-02492-4.","journal-title":"Leukemia"},{"key":"4283_CR60","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1182\/blood-2018-01-791376","volume":"131","author":"D Rossi","year":"2018","unstructured":"Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018;131:2761\u201372. https:\/\/doi.org\/10.1182\/blood-2018-01-791376.","journal-title":"Blood"},{"key":"4283_CR61","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.2019.224121","volume":"105","author":"Y Wang","year":"2020","unstructured":"Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020;105:765\u201373. https:\/\/doi.org\/10.3324\/haematol.2019.224121.","journal-title":"Haematologica"},{"key":"4283_CR62","doi-asserted-by":"publisher","first-page":"e12701","DOI":"10.1097\/MD.0000000000012701","volume":"97","author":"L Xu","year":"2018","unstructured":"Xu L, Song JC, Sun XH, Gao ZF, Lv L, Zhu J. Richter\u2019s syndrome of the central nervous system diagnosed concurrently with chronic lymphocytic leukaemia. Medicine (Baltimore). 2018;97:e12701. https:\/\/doi.org\/10.1097\/MD.0000000000012701.","journal-title":"Medicine (Baltimore)"},{"key":"4283_CR63","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1182\/hematology.2022000345","volume":"2022","author":"PA Thompson","year":"2022","unstructured":"Thompson PA, Siddiqi T. Treatment of Richter\u2019s syndrome. Hematology (United States). 2022;2022:329\u201336. https:\/\/doi.org\/10.1182\/hematology.2022000345.","journal-title":"Hematology (United States)"},{"key":"4283_CR64","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3960\/jslrt.22017","volume":"62","author":"Y Nato","year":"2022","unstructured":"Nato Y, Nagaharu K, Inoue K, Yabu K, Sawaki A, Shiotani T, et al. An experience with ibrutinib monotherapy for Richter\u2019s syndrome isolated in the central nervous system. J Clin Exp Hematopathol. 2022;62:238\u201341. https:\/\/doi.org\/10.3960\/jslrt.22017.","journal-title":"J Clin Exp Hematopathol"},{"key":"4283_CR65","doi-asserted-by":"publisher","first-page":"1635589","DOI":"10.3389\/fimmu.2025.1635589","volume":"16","author":"K Lu","year":"2025","unstructured":"Lu K, Chen P, Zhang X, Zheng W, Zhang L, Wu X, et al. Glofitamab treatment of Richter transformation with isolated central nervous system involvement: a case report. Front Immunol. 2025;16:1635589. https:\/\/doi.org\/10.3389\/fimmu.2025.1635589.","journal-title":"Front Immunol"},{"key":"4283_CR66","unstructured":"Inc MG. PRELIMINARY RESULTS OF THE ONGOING MULTICENTER, PHASE 2 STUDY OF... by Dr. Matthew Davids [Internet]. [cited 2025 Aug 17]. https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4159982\/matthew.davids.preliminary.results.of.the.ongoing.multicenter.phase.2.study.of.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D2%2Asearch%3Ddavids. Accessed 17 Aug 2025"},{"key":"4283_CR67","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S1470-2045(24)00070-6","volume":"25","author":"AP Kater","year":"2024","unstructured":"Kater AP, Arslan \u00d6, Demirkan F, Herishanu Y, Ferhanoglu B, Diaz MG, et al. Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial. Lancet Oncol. 2024;25:463\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(24)00070-6.","journal-title":"Lancet Oncol"},{"key":"4283_CR68","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.3390\/cancers17193159","volume":"17","author":"M Dimou","year":"2025","unstructured":"Dimou M, Fioretzaki R, Zerzi C, Konstantinou E, Asimakopoulos JV, Arapaki M, et al. Venetoclax-rituximab and emerging treatment strategies after c-BTKi exposure in relapsed\/refractory CLL: a real-world cohort and literature overview. Cancers (Basel). 2025;17:3159. https:\/\/doi.org\/10.3390\/cancers17193159.","journal-title":"Cancers (Basel)"},{"key":"4283_CR69","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025482","author":"M Shadman","year":"2025","unstructured":"Shadman M, Davids MS. How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2024025482.","journal-title":"Blood"},{"key":"4283_CR70","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1182\/bloodadvances.2024015493","volume":"9","author":"M Shadman","year":"2025","unstructured":"Shadman M, Burke JM, Cultrera J, Yimer HA, Zafar SF, Misleh J, et al. Zanubrutinib is well tolerated and effective in patients with CLL\/SLL intolerant of ibrutinib\/acalabrutinib: updated results. Blood Adv. 2025;9:4100\u201310. https:\/\/doi.org\/10.1182\/bloodadvances.2024015493.","journal-title":"Blood Adv"},{"key":"4283_CR71","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1182\/bloodadvances.2024014206","volume":"9","author":"JR Brown","year":"2025","unstructured":"Brown JR, Li J, Eichhorst BF, Lamanna N, O\u2019Brien SM, Tam CS, et al. Acquired mutations in patients with relapsed\/refractory CLL who progressed in the ALPINE study. Blood Adv. 2025;9:1918\u201326. https:\/\/doi.org\/10.1182\/bloodadvances.2024014206.","journal-title":"Blood Adv"},{"key":"4283_CR72","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood.2023023659","volume":"144","author":"JA Woyach","year":"2024","unstructured":"Woyach JA, Jones D, Jurczak W, Robak T, Ill\u00e9s \u00c1, Kater AP, et al. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Blood. 2024;144:1061\u20138. https:\/\/doi.org\/10.1182\/blood.2023023659.","journal-title":"Blood"},{"key":"4283_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2025.05.009","author":"JR Brown","year":"2025","unstructured":"Brown JR. Resistance to Bruton tyrosine kinase inhibitors. Hematol Oncol Clin North Am. 2025. https:\/\/doi.org\/10.1016\/j.hoc.2025.05.009.","journal-title":"Hematol Oncol Clin North Am"},{"key":"4283_CR74","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","volume":"126","author":"T-M Liu","year":"2015","unstructured":"Liu T-M, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, et al. Hypermorphic mutation of phospholipase C, \u03b32 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. 2015;126:61\u20138. https:\/\/doi.org\/10.1182\/blood-2015-02-626846.","journal-title":"Blood"},{"key":"4283_CR75","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, et al. Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 2023;389:33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2300696.","journal-title":"N Engl J Med"},{"key":"4283_CR76","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1200\/JCO-25-00166","volume":"43","author":"JP Sharman","year":"2025","unstructured":"Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, et al. Phase III trial of pirtobrutinib versus idelalisib\/rituximab or bendamustine\/rituximab in covalent Bruton tyrosine kinase inhibitor\u2013pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321). J Clin Oncol. 2025;43:2538\u201349. https:\/\/doi.org\/10.1200\/JCO-25-00166.","journal-title":"J Clin Oncol"},{"key":"4283_CR77","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.3324\/haematol.2023.284150","volume":"109","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Jen M-H, Hess LM, Zhang J, Goebel B, Pagel JM, et al. Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison. Haematologica. 2024;109:1866\u201373. https:\/\/doi.org\/10.3324\/haematol.2023.284150.","journal-title":"Haematologica"},{"key":"4283_CR78","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.clml.2022.09.007","volume":"23","author":"AR Mato","year":"2023","unstructured":"Mato AR, Hess LM, Chen Y, Abada PB, Konig H, Pagel JM, et al. Outcomes for patients with chronic lymphocytic leukemia (CLL) previously treated with both a covalent BTK and BCL2 inhibitor in the United States: a real-world database study. Clin Lymphoma Myeloma Leuk. 2023;23:57\u201367. https:\/\/doi.org\/10.1016\/j.clml.2022.09.007.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4283_CR79","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jtct.2025.06.002","volume":"31","author":"MA Kharfan-Dabaja","year":"2025","unstructured":"Kharfan-Dabaja MA, Kumar A, Pinilla-Ibarz J, Brown JR, Shadman M, Awan FT, et al. Clinical practice recommendations on the role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy in patients with chronic lymphocytic leukemia on behalf of the American society for transplantation and cellular therapy. Transplant Cell Ther. 2025;31:494\u2013504. https:\/\/doi.org\/10.1016\/j.jtct.2025.06.002.","journal-title":"Transplant Cell Ther"},{"key":"4283_CR80","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023;402:641\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(23)01052-8.","journal-title":"Lancet"},{"key":"4283_CR81","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1182\/blood-2023-179529","volume":"142","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, et al. Lisocabtagene maraleucel (liso-cel) in R\/R CLL\/SLL: 24-month median follow-up of TRANSCEND CLL 004. Blood. 2023;142:330. https:\/\/doi.org\/10.1182\/blood-2023-179529.","journal-title":"Blood"},{"key":"4283_CR82","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/bloodadvances.2024014164","volume":"9","author":"PA Riedell","year":"2024","unstructured":"Riedell PA, Grady CB, Nastoupil LJ, Luna A, Ahmed N, Maziarz RT, et al. Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv. 2024;9:1232\u201341. https:\/\/doi.org\/10.1182\/bloodadvances.2024014164.","journal-title":"Blood Adv"},{"key":"4283_CR83","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1200\/JCO.23.02214","volume":"42","author":"M Wang","year":"2024","unstructured":"Wang M, Siddiqi T, Gordon LI, Kamdar M, Lunning M, Hirayama AV, et al. Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma (MCL): primary analysis of the MCL cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol Off J Am Soc Clin Oncol. 2024;42:1146\u201357. https:\/\/doi.org\/10.1200\/JCO.23.02214.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4283_CR84","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","volume":"116","author":"P Dreger","year":"2010","unstructured":"Dreger P, D\u00f6hner H, Ritgen M, B\u00f6ttcher S, Busch R, Dietrich S, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116:2438\u201347. https:\/\/doi.org\/10.1182\/blood-2010-03-275420.","journal-title":"Blood"},{"key":"4283_CR85","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood.V130.Suppl_1.667.667","volume":"130","author":"HT Kim","year":"2017","unstructured":"Kim HT, Hu Z-H, Woo Ahn K, Davids M, Volpe V, Alyea E, et al. Prognostic score and cytogenetic risk classification for chronic lymphocyteic leukemia patients who underwent reduced intensity conditioning allogeneit HCT: a CIBMTR report. Blood. 2017;130:667. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.667.667.","journal-title":"Blood"},{"key":"4283_CR86","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/JCO.18.01460","volume":"37","author":"JP Sharman","year":"2019","unstructured":"Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019;37:1391\u2013402. https:\/\/doi.org\/10.1200\/JCO.18.01460.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04283-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04283-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04283-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:53:10Z","timestamp":1793281990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04283-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":86,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4283"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04283-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no financial or non-financial interests that are directly or indirectly related to the work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}